Words such as believes.

These statements are based on management’s current beliefs and expectations. These forward-looking statements include statements regarding enrollment, conduct and completion of clinical trials, Contrave, the timing of an NDA with the FDA for Contrave, the efficacy and safety of Contrave, and the potential regulatory approval is, and effectively treat obesity, Contrave. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties in the Company’s business, including, without limitation: and timing of the and timing of the company’s Contrave clinical trials or the development of Contrave the potential for adverse safety findings relating to delay in Contrave or prevent regulatory filings and its licensors do not get to be in maintain maintain and successfully enforce adequate patent protection and intellectual property protection of its product candidates and other risks that the in described in the Company’s filings with the Securities and Exchange Commission .

NB-303 is a placebo-controlled, to analyze 56 – week clinical trial evaluating the efficacy, safety and tolerability of Contrave at the expected standard dose, change with the possibility of for the patient to a higher dose, if it does not respond after 28 weeks of therapy. This study is at 36 centers nationwide and has conducted randomized approximately 1495 patients.On the other hand, Holmes ‘ lawyer arguing that their client has for the force on to the drug, in which case such will be definitive appoint to try to attract a verdict the temporary incapacitation forced.

Other entries from category "urology":

Random entries